Safety of intravenous and subcutaneous belimumab in Japanese patients with systemic lupus erythematosus: Final analysis of data from an all-case post-marketing surveillance study

Clicks: 2
ID: 325630
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #32 of 36 articles by views in modern rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To assess safety of belimumab in Japanese patients with systemic lupus erythematosus (SLE) in real-world clinical practice. METHODS: This all-case post-marketing surveillance study included patients initiating belimumab between December 2017 and October 2018. To evaluate safety, patients were observed for up to 52 weeks. In main population, baseline risk factors for serious infection were assessed by multivariate analysis. Exploratory risk factor analysis for depression/suicidal ideation/suicide attempt was conducted in expanded population. RESULTS: Among 1177 patients (main population), incidence rates per 100 person-years of serious adverse events (SAEs) and AEs of special interest were: SAEs, 28.4; serious infection, 8.8; depression/suicidal ideation/suicide attempt, 1.3; malignant tumour, 0.7; serious hypersensitivity, 0.7. Male sex, any comorbidity and glucocorticoid dose at baseline were independent risk factors for serious infection. In exploratory analysis, comorbidity of depression/suicidal ideation/suicide attempt at belimumab initiation was an associated characteristic factor for the new occurrence/worsening depression/suicidal ideation/suicide attempt. CONCLUSIONS: No new safety concerns were identified compared with previously reported data and current belimumab labelling. Depression/suicidal ideation/suicide attempt incidence rate was similar to that previously reported for patients with SLE. Patients with risk factors for serious infection and depression/suicidal ideation/suicide attempt should be carefully monitored.Clinicaltrials.gov: NCT03370263.
Reference Key
openalex_W7203741750 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nami Okamoto, Takao Fujii, Tatsuya Atsumi, Asami Abe, Nobunori Takahashi, Naoto Tamura, Atsuo Nakajima, Ayako Nakajima, Shingo Nakayamada, Keiichiro Nishida, Hiroaki Matsuno, Tomohiko Asamura, Megumi Koyano, Ai Hayashi, Mitsuhiro Yoshida, Daisuke Noda, Naoki Kaneko, Shuntaro Saito, Michiaki Takagi, Sakae Tanaka, Tsutomu Takeuchi, Yoshiya Tanaka, Masataka Kuwana
Journal modern rheumatology
Year 2026
DOI
10.1093/mr/roag066
URL
https://doi.org/10.1093/mr/roag066
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.